Associated Papers
Second-Generation Tyrosine Kinase Inhibitors (Tki) as Salvage Therapy for Resistant or Intolerant Patients to Prior TKIs.
Breccia M et al.
Mediterranean Journal of Hematology and Infectious Diseases, 2014
Three novel patient-derived BCR/ABL mutants show different sensitivity to second and third generation tyrosine kinase inhibitors.
Redaelli S et al.
American Journal of Hematology, 2012
Dynamics of BCR-ABL kinase domain mutations in chronic myeloid leukemia after sequential treatment with multiple tyrosine kinase inhibitors.
Cortes J et al.
Blood, 2007
Select a paper to view details